Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) confirmed on Wednesday that it plans to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren's disease (SjD).
This decision follows an analysis of topline data from the Phase 2 RHO study which showed favourable safety, efficacy and biomarker results, confirming the therapeutic potential of efgartigimod.
With primary Sjogren's disease lacking FDA-approved treatments, efgartigimod offers promise as a potential alternative therapy for patients.
Sjogren's disease, characterised by immune-mediated destruction of exocrine glands, predominantly affects women. Common symptoms include dry eyes and mouth, fatigue, joint point and impaired cognitive function, and a substantial subset of patients suffer from extraglandular systemic disease.
Designed to target disease-causing immunoglobulin G antibodies, efgartigimod has demonstrated clinical efficacy across multiple endpoints.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member